Moleculin Abstract Accepted for Poster Presentation at the European Hematology Association (EHA) 2024 Hybrid Congress
Moleculin Abstract Accepted for Poster Presentation at the European Hematology Association (EHA) 2024 Hybrid Congress
HOUSTON, May 16, 2024 — Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced its abstract has been accepted for poster presentation at the EHA2024 Hybrid Congress being held June 13-16, 2024 in Madrid, Spain and virtually.
休斯頓，2024 年 5 月 16 日 — Moleculin Biotech有限公司，（納斯達克股票代碼：MBRX）（“Moleculin” 或 “公司”）是一家臨床階段的製藥公司，擁有廣泛的針對難以治療的腫瘤和病毒的候選藥物組合，今天宣佈其摘要已獲准在會上作海報展示 EHA2024 混合大會 將於 2024 年 6 月 13 日至 16 日在西班牙馬德里以虛擬方式舉行。
Details for the poster presentation are as follows:
海報展示詳情如下：
Abstract: P537
Session: Acute myeloid leukemia – Clinical
Title: LIPOSOMAL ANNAMYCIN (L-ANN) IN COMBINATION WITH CYTARABINE FOR TREATMENT OF PATIENTS WITH ACUTE MYELOID LEUKAEMIA (AML) REFACTORY TO OR RELAPSED (R/R) AFTER INDUCTION THERAPY (MB-106 STUDY)
Presenting Author: Wolfram C. M. Dempke, MD, PhD, MBA, European Chief Medical Officer of Moleculin
摘要： P537
會話： 急性髓系白血病 — 臨床
標題： 脂質體安那黴素（L-ANN）與阿糖胞苷聯合用於治療誘導治療後急性髓系白血病（AML）復發或復發（R/R）患者（MB-106 研究）
主講作者： Wolfram C. M. Dempke，醫學博士，工商管理碩士，Moleculin 歐洲首席醫學官
For more information about the EHA2024 Hybrid Congress, visit the event website.
有關 EHA2024 混合大會的更多信息，請訪問 活動網站。
About Moleculin Biotech, Inc.
關於 Moleculin Biotech, Inc.
Moleculin Biotech, Inc. is a clinical stage pharmaceutical company with a growing pipeline, including Phase 2 clinical programs, for hard-to-treat tumors and viruses. The Company's lead program, Annamycin is a next-generation anthracycline designed to avoid multidrug resistance mechanisms and to eliminate the cardiotoxicity common with currently prescribed anthracyclines. Annamycin is currently in development for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases. All interim and preliminary data discussed above are subject to change.
Moleculin Biotech, Inc. 是一家臨床階段的製藥公司，針對難以治療的腫瘤和病毒的產品線不斷擴大，包括二期臨床項目。該公司的主要項目安那黴素是下一代蒽環素，旨在避免多藥耐藥機制，並消除目前處方蒽環類藥物常見的心臟毒性。安那黴素目前正在開發中，用於治療復發或難治性急性髓系白血病（AML）和軟組織肉瘤（STS）肺轉移。上面討論的所有中期和初步數據可能會發生變化。
Additionally, the Company is developing WP1066, an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other oncogenic transcription factors while also stimulating a natural immune response, targeting brain tumors, pancreatic and other cancers, and WP1220, an analog to WP1066, for the topical treatment of cutaneous T-cell lymphoma. Moleculin is also engaged in the development of a portfolio of antimetabolites, including WP1122 for the potential treatment of viruses, as well as cancer indications including brain tumors, pancreatic and other cancers.
此外，該公司正在開發免疫/轉錄調節劑 WP1066，一種免疫/轉錄調節劑，能夠抑制p-stat3和其他致癌轉錄因子，同時刺激針對腦腫瘤、胰腺和其他癌症的自然免疫反應，以及用於局部治療皮膚 T 細胞淋巴瘤的 WP1066 類似物 WP1220。Moleculin 還參與開發抗代謝藥物產品組合，包括用於潛在病毒治療的 WP1122，以及包括腦腫瘤、胰腺癌和其他癌症在內的癌症適應症。
For more information about the Company, please visit www.moleculin.com and connect on Twitter, LinkedIn and Facebook.
如需了解有關公司的更多信息，請訪問 www.moleculin.com 然後連接 推特， 領英 和 Facebook。
Investor Contact:
投資者聯繫人：
JTC Team, LLC
Jenene Thomas
(833) 475-8247
MBRX@jtcir.com
JTC Team, LLC
珍妮·托馬斯
(833) 475-8247
MBRX@jtcir.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/moleculin-abstract-accepted-for-poster-presentation-at-the-european-hematology-association-eha-2024-hybrid-congress-302146725.html
SOURCE Moleculin Biotech, Inc.
來源 Moleculin Biotech, Inc.
譯文內容由第三人軟體翻譯。